• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172855 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
. p! g& p3 w( B) C. a9 y% x, i6 }
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
2 h) J, u5 _& L6 v9 ~& G2 {) K& u# H* p
8 w& r5 e% P) I) N( R4 n2 ~: N
Sub-category:
$ f  h# Y" `4 U& a( x- Z. lMolecular Targets
- N3 G2 ^  G; k+ A- Z& U) z& E& a; z7 |& G9 j2 A
: S& S% @8 r' m8 N8 {) B! ]
Category:
/ d8 o$ q& ?( F. b) C3 _1 lTumor Biology 5 ^8 }2 }; m0 W+ n, t

+ ^$ X1 @2 x1 m& `6 @
+ ^) Y; E' o3 @) ]Meeting:) U) H- y. G; o) c5 J
2011 ASCO Annual Meeting
; z+ B0 B, X" F$ a( N* i- x* p1 |; v$ X  r9 ^$ Y+ O; ]& r
! c! q" I0 A4 u8 ]$ p
Session Type and Session Title:4 b7 j! t) T  |
Poster Discussion Session, Tumor Biology
$ m  @& Y, b8 }  }$ Z( J
/ d2 }3 T2 _3 C. g& ^$ U- M. A! c6 F
Abstract No:
2 \  s) Y7 p1 }$ H9 }10517 ! [( U7 k: d1 g6 i  S$ v# [

( B1 I! Z. o. R1 @
. p7 K# l1 l7 _' r8 a& n' _Citation:
) G$ Y) Q4 s( C- C( T* }) UJ Clin Oncol 29: 2011 (suppl; abstr 10517)
8 Z% t# u1 K' e' w! z' t- ]
8 ?# w  Y" C# v. n0 `, Q$ z) [8 K& i
Author(s):
, }$ n5 y5 ]. h, k7 r& jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 A6 h6 t: y+ e) z; G, \- }" d+ V& L8 t: T3 u$ l
) T/ ^2 @! L6 G' b$ M1 f, o
. y5 h4 E, g1 V) ~7 b5 y+ e
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
- c( j, J8 F0 j& m1 Y, h$ A% j. N1 Q+ t' b: N
Abstract Disclosures* t  W3 |, _  c% m  P4 c% n  g8 `

+ x2 a) [) A7 o7 [, |Abstract:5 q& M; }; a% B& {

- [* @7 y% B( p4 k, l, `7 y2 L& f& [. q" @" f- O* Z8 a
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 @0 q9 @6 j7 F) |- a( p( ]6 d
$ w, M2 b7 r, q8 {# {# l
5 j/ j& _; Y! p- S" [  O+ H
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
  b0 W* l5 C) k没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

9 r8 |. ?. I) D1 I2 J化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
3 d* N" B- d( y* a7 E, N易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
+ t! [+ [+ I7 m+ U7 oALK一个指标医院要900多 ...
3 }( F) `9 p5 p( {' S1 g$ T; R7 q- K
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
* l: _8 L7 g4 X6 r* v
) K6 Y0 y, |! ~# @- |现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表